Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer

Chinese Academy of Medical Sciences160 enrolled

Overview

This is a phase II study to assess efficacy/safety of Exemestane with or without Aspirin as the adjuvant treatment in postmenopausal breast cancer patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

160

Conditions

Breast Neoplasms

Interventions

aspirinDRUG

Aspirin 50mg po daily

ExemestaneDRUG

Exemestane 25mg po daily

Eligibility

Sex: FEMALEMin age: 50 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Breast cancer after surgery postmenopausal Exclusion Criteria: * contraindication of aspirin

Locations (1)

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Beijing, China

RECRUITING

Outcomes

Primary Outcomes

Quality of Life

Time frame: 4 years

Central Contacts

Peng Yuan, M.D.

CONTACT

86-135 0127 0834 yuanpeng01@hotmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.